15353-j-veluchamy

6 General discussion and Future Prospects | 161 Oncology (2015) 8 (1):130. doi: 10.1186/s13045-015-0227-0. 55. Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood (2015) 125 (26):4024-31. Epub 2015/04/19. doi: 10.1182/ blood-2014-12-614636. PubMed PMID: 25887777; PubMed Central PMCID: PMCPMC4528081. 56. Martin DW, Williams SR. Non-natural MIC proteins . Google Patents (2014). 57. Sola C, Chanuc F, Thielens A, Fuseri N, Morel Y, Bléry M, et al. Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. Journal for immunotherapy of cancer (2013) 1 (Suppl 1):P40-P. doi: 10.1186/2051-1426-1- S1-P40. PubMed PMID: PMC3991278. 58. Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol (2008) 32 (3):633-41. Epub 2008/02/23. PubMed PMID: 18292941. 59. GoodenM, LampenM, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A (2011) 108 (26):10656-61. Epub 2011/06/15. doi: 10.1073/pnas.1100354108. PubMed PMID: 21670276; PubMed Central PMCID: PMCPmc3127933. 60. Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai Y-T, Shi J, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal transition-like transcriptional activation. Cell reports (2015) 12 (4):622-35. doi: 10.1016/j.celrep.2015.06.059. PubMed PMID: PMC4961259. 61. Marasca R, Maffei R. NOX-A12: mobilizing CLL away from home. Blood (2014) 123 (7):952-3. doi: 10.1182/blood-2013-12-542480. 62. Chou T-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research (2010) 70 (2):440-6. doi: 10.1158/0008-5472.can-09-1947. 63. Ng ES, Davis RP, Azzola L, Stanley EG, Elefanty AG. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood (2005) 106(5):1601–3. doi:10.1182/blood-2005-03-0987. 64. Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol (2005) 175(8):5095–103. doi:10.4049/ jimmunol.175.8.5095. 65. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood (2009) 113(24):6094–101. doi:10.1182/blood-2008-06-165225 66. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med (2013) 2(4):274–83. doi:10.5966/sctm.2012-0084